Back to search
FDAFDA · Food and drugs·Recall number D-0277-2025

Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC 57237-018-99

Published March 26, 2025 · Recall initiated: March 5, 2025

Summary

FDA records drug Class II recall D-0277-2025, published March 26, 2025 and initiated March 5, 2025. Recalling firm: Rising Pharma Holding, Inc.; Status: Ongoing; Reported quantity: 1223 bottles; Lot: Lot #: DTB23111A, Exp 8/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Rising Pharma Holding, Inc.
Distributor
Nationwide in the USA.
Lot
Lot #: DTB23111A, Exp 8/31/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC 57237-018-99 recalled?

Yes. FDA published recall D-0277-2025 on March 26, 2025. Reported hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter